• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞内酪氨酸在激活 KIT 诱导的骨髓增生性疾病中的作用。

Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.

机构信息

Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.

出版信息

Leukemia. 2012 Jul;26(7):1499-1506. doi: 10.1038/leu.2012.22. Epub 2012 Feb 2.

DOI:10.1038/leu.2012.22
PMID:22297723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4378686/
Abstract

Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal stromal tumors, systemic mastocytosis and acute myelogenous leukemia. The intracellular signals that contribute to oncogenic KIT-induced myeloproliferative disease (MPD) are poorly understood. Here, we show that oncogenic KITD814V-induced MPD occurs in the absence of ligand stimulation. The intracellular tyrosine residues are important for KITD814V-induced MPD, albeit to varying degrees. Among the seven intracellular tyrosines examined, tyrosine 719 alone has a unique role in regulating KITD814V-induced proliferation and survival in vitro, and MPD in vivo. Importantly, the extent to which AKT, extracellular signal-regulated kinase and Stat5 signaling pathways are activated via the seven intracellular tyrosines in KITD814V impacts the latency of MPD and severity of the disease. Our results identify critical signaling molecules involved in regulating KITD814V-induced MPD, which might be useful for developing novel therapeutic targets for hematologic malignancies involving this mutation.

摘要

人类 KIT 受体的功能获得性突变与胃肠道间质肿瘤、全身性肥大细胞增多症和急性髓性白血病有关。导致致癌性 KIT 诱导的骨髓增生性疾病(MPD)的细胞内信号仍知之甚少。在这里,我们表明,在没有配体刺激的情况下,致癌性 KITD814V 诱导的 MPD 发生。细胞内的酪氨酸残基对于 KITD814V 诱导的 MPD 很重要,尽管程度不同。在研究的七个细胞内酪氨酸中,只有酪氨酸 719 在体外调节 KITD814V 诱导的增殖和存活以及体内 MPD 方面具有独特的作用。重要的是,通过 KITD814V 中的七个细胞内酪氨酸激活的 AKT、细胞外信号调节激酶和 Stat5 信号通路的程度会影响 MPD 的潜伏期和疾病的严重程度。我们的研究结果确定了参与调节 KITD814V 诱导的 MPD 的关键信号分子,这可能有助于开发涉及这种突变的血液恶性肿瘤的新型治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/c9e938c6e8d0/nihms-353129-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/d835bae1560d/nihms-353129-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/1b07b57840a2/nihms-353129-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/b91d191c23e5/nihms-353129-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/ce7339ffe246/nihms-353129-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/c9e938c6e8d0/nihms-353129-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/d835bae1560d/nihms-353129-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/1b07b57840a2/nihms-353129-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/b91d191c23e5/nihms-353129-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/ce7339ffe246/nihms-353129-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd96/4378686/c9e938c6e8d0/nihms-353129-f0005.jpg

相似文献

1
Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.细胞内酪氨酸在激活 KIT 诱导的骨髓增生性疾病中的作用。
Leukemia. 2012 Jul;26(7):1499-1506. doi: 10.1038/leu.2012.22. Epub 2012 Feb 2.
2
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.SHP2 磷酸酶在 KIT 诱导的转化中的作用:鉴定 SHP2 作为涉及致癌性 KIT 的疾病中的可用药靶。
Blood. 2012 Sep 27;120(13):2669-78. doi: 10.1182/blood-2011-08-375873. Epub 2012 Jul 17.
3
Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.KIT激活环突变驱动的骨髓增殖性疾病中IA类PI3K的p85α调节亚基的需求
Exp Hematol. 2008 Mar;36(3):301-8. doi: 10.1016/j.exphem.2007.11.008. Epub 2008 Jan 7.
4
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.E3 连接酶缺陷型 Cbl 突变体导致全身性肥大细胞增多症和骨髓增殖性疾病。
Blood. 2009 Nov 5;114(19):4197-208. doi: 10.1182/blood-2008-12-190934. Epub 2009 Sep 4.
5
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.遗传和药理学证据表明,在急性髓系白血病和系统性肥大细胞增多症中,PI3K的p85α调节亚基而非p85β调节亚基以及Rac2 GTP酶参与调控致癌性KIT诱导的细胞转化。
Blood. 2007 Sep 1;110(5):1612-20. doi: 10.1182/blood-2006-10-053058. Epub 2007 May 4.
6
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.慢性粒细胞白血病和肥大细胞增多症中协同作用的STAT5和AKT信号通路:可能的新治疗靶点。
Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442.
7
Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.c-Kit 激活环酪氨酸 823 的磷酸化对于细胞存活和增殖至关重要。
J Biol Chem. 2013 Aug 2;288(31):22460-8. doi: 10.1074/jbc.M113.474072. Epub 2013 Jun 26.
8
Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.慢性骨髓增殖性肿瘤中磷酸化 STAT5 和磷酸化 Akt 的表达。
Br J Haematol. 2009 Nov;147(4):495-506. doi: 10.1111/j.1365-2141.2009.07870.x. Epub 2009 Aug 31.
9
Lipid rafts are required for Kit survival and proliferation signals.脂筏是Kit生存和增殖信号所必需的。
Blood. 2007 Sep 15;110(6):1739-47. doi: 10.1182/blood-2006-05-020925. Epub 2007 Jun 6.
10
Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.酪氨酸719和磷脂酰肌醇3'-激酶介导的信号通路在Asp814Val突变型c-kit受体酪氨酸激酶的组成性激活和致癌潜能中的必要性。
Blood. 2003 Feb 1;101(3):1094-102. doi: 10.1182/blood-2002-01-0177. Epub 2002 Sep 12.

引用本文的文献

1
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.PRL2 磷酸酶通过调节 CBL 磷酸化促进白血病细胞中的致癌 KIT 信号。
Mol Cancer Res. 2024 Jan 2;22(1):94-103. doi: 10.1158/1541-7786.MCR-23-0115.
2
Sterile α-motif domain requirement for cellular signaling and survival.无菌α-motif 结构域对细胞信号转导和存活的要求。
J Biol Chem. 2020 May 15;295(20):7113-7125. doi: 10.1074/jbc.RA119.011895. Epub 2020 Apr 2.
3
Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

本文引用的文献

1
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.Rho 激酶调节携带致癌形式 KIT、FLT3 和 BCR-ABL 的细胞的存活和转化。
Cancer Cell. 2011 Sep 13;20(3):357-69. doi: 10.1016/j.ccr.2011.07.016.
2
c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.c-Kit 突变体需要缺氧诱导因子 1α 来转化黑素细胞。
Oncogene. 2010 Jan 14;29(2):227-36. doi: 10.1038/onc.2009.320. Epub 2009 Oct 5.
3
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
突变型 KIT 直接激活 PI3K 通路在胃肠道间质瘤的致癌信号中占主导地位。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8448-E8457. doi: 10.1073/pnas.1711449114. Epub 2017 Sep 18.
4
Hematopoietic Signaling Mechanism Revealed from a Stem/Progenitor Cell Cistrome.从干细胞/祖细胞染色质组揭示的造血信号机制。
Mol Cell. 2015 Jul 2;59(1):62-74. doi: 10.1016/j.molcel.2015.05.020. Epub 2015 Jun 11.
5
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.靶向磷脂酰肌醇-3-激酶通路治疗费城染色体阴性骨髓增殖性肿瘤
Mol Cancer. 2015 Jun 11;14:118. doi: 10.1186/s12943-015-0388-z.
6
Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.再生肝脏磷酸酶在造血干细胞和血液系统恶性肿瘤中的作用
Cell Cycle. 2014;13(18):2827-35. doi: 10.4161/15384101.2014.954448.
7
PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.PRL2/PTP4A2磷酸酶对造血干细胞自我更新很重要。
Stem Cells. 2014 Jul;32(7):1956-67. doi: 10.1002/stem.1672.
8
Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.Pak 和 Rac GTPases 促进致癌性 KIT 诱导的肿瘤形成。
J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.
致癌性Kit通过Stat5/PI3激酶信号级联反应控制肿瘤性肥大细胞的生长。
Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25.
4
Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.KIT激活环突变驱动的骨髓增殖性疾病中IA类PI3K的p85α调节亚基的需求
Exp Hematol. 2008 Mar;36(3):301-8. doi: 10.1016/j.exphem.2007.11.008. Epub 2008 Jan 7.
5
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.遗传和药理学证据表明,在急性髓系白血病和系统性肥大细胞增多症中,PI3K的p85α调节亚基而非p85β调节亚基以及Rac2 GTP酶参与调控致癌性KIT诱导的细胞转化。
Blood. 2007 Sep 1;110(5):1612-20. doi: 10.1182/blood-2006-10-053058. Epub 2007 May 4.
6
Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.Kit蛋白酪氨酸激酶(干细胞因子受体)的结构与调控
Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15. doi: 10.1016/j.bbrc.2005.09.150. Epub 2005 Oct 4.
7
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.由Shp2(PTPN11)突变引发的白血病小鼠模型的预后、治疗及机制研究意义
Cancer Cell. 2005 Feb;7(2):179-91. doi: 10.1016/j.ccr.2005.01.010.
8
Synergistic growth of stem cell factor and granulocyte macrophage colony-stimulating factor involves kinase-dependent and -independent contributions from c-Kit.干细胞因子与粒细胞巨噬细胞集落刺激因子的协同生长涉及c-Kit的激酶依赖性和非依赖性作用。
J Biol Chem. 2004 Oct 22;279(43):44544-53. doi: 10.1074/jbc.M404085200. Epub 2004 Aug 12.
9
c-Kit-mediated overlapping and unique functional and biochemical outcomes via diverse signaling pathways.c-Kit 通过多种信号通路介导重叠且独特的功能和生化结果。
Mol Cell Biol. 2004 Feb;24(3):1401-10. doi: 10.1128/MCB.24.3.1401-1410.2004.
10
Functional and biochemical consequences of abrogating the activation of multiple diverse early signaling pathways in Kit. Role for Src kinase pathway in Kit-induced cooperation with erythropoietin receptor.消除Kit中多种不同早期信号通路激活的功能和生化后果。Src激酶通路在Kit诱导的与促红细胞生成素受体协同作用中的作用。
J Biol Chem. 2003 Mar 28;278(13):11686-95. doi: 10.1074/jbc.M207068200. Epub 2002 Dec 13.